药物与在患有微观结肠炎的患者中重复治疗布松胺之间的关联:一项追溯观察性研究
Oliver Bjurström1, Pontus Karling2
1Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
Therapeutic advances in gastroenterology
|March 21, 2024
概括
非类固醇抗炎药物 (NSAIDs) 增加了微观结肠炎 (MC) 复发的风险,需要重复治疗. 其他常用药物如阿司匹林,质子抑制剂,SSRI和他类药物与MC复发无关.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 微观性结肠炎 (MC) 是一种与吸烟和某些药物有关的疾病.
- 常见的相关药物包括非类固醇抗炎药物 (NSAIDs),乙盐酸 (ASA),质子抑制剂 (PPIs),血清素再吸收抑制剂 (SSRI) 和他类药物.
研究的目的:
- 调查这些风险因素与MC患者重复接受布索尼德治疗之间的关联.
- 为了确定特定的药物是否会影响后续布德索尼德疗程的需要.
主要方法:
- 在2006年至2022年期间诊断的183名MC患者的回顾性观察研究.
- 基线因素和诊断前后药物使用的分析.
- 根据风险因素,研究了接受口服布德索尼德的几率,并根据风险因素要求进行第二次治疗.
主要成果:
- 75%的患者接受了布迪索尼德,49%的患者出现了需要复发的复发.
- 在复发后一年内使用NSAID显著增加了复发几率 (OR:3.70).
- 在ASA,PPI,SSRI,他类药物或吸烟与MC复发或初始布德森尼德处方之间没有发现显著的关联.
结论:
- 使用NSAID与显微性结肠炎复发的风险增加有关,需要重复的布索尼德治疗.
- 乙盐酸 (ASA),质子抑制剂 (PPI),血清素再吸收抑制剂 (SSRI) 和他类药物似乎不会增加MC复发或重复布索尼德治疗的风险.
相关概念视频
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
118
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
118
01:29Drugs for Treatment of Ulcerative Colitis in IBD
139
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
139
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
163
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
163
01:21Drugs for Treatment of Constipation-Predominant IBS
162
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
162
01:29Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
01:17Drugs for Treatment of Diarrhea-Predominant IBS
167
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
167